Panitumumab IRDye800 Optical Imaging Study

Trial ID or NCT#



not recruiting iconNOT RECRUITING


Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.

Official Title

Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


John B. Sunwoo, MD
John B. Sunwoo, MD
Head and neck surgeon
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor, by courtesy, of Dermatology
Davud Sirjani, MD
Davud Sirjani, MD
Head and neck surgeon
Clinical Professor, Otolaryngology (Head and Neck Surgery)
Vasu Divi, MD
Vasu Divi, MD
Head and neck surgeon
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Michael J. Kaplan, MD

Contact us to find out if this trial is right for you.


Grace Yi